EQRx, Inc. (EQRX)

NASDAQ: EQRX · IEX Real-Time Price · USD
4.84 0.23 (4.88%)
Jan 25, 2022 9:56 AM EST - Market open
Market Cap333.62M
Revenue (ttm)n/a
Net Income (ttm)-202.91M
Shares Out69.00M
EPS (ttm)-7.65
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume84,777
Open4.50
Previous Close4.61
Day's Range4.60 - 4.85
52-Week Range3.98 - 8.70
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About EQRX

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinic...

IndustryBiotechnology
Founded2019
Employees216
Stock ExchangeNASDAQ
Ticker SymbolEQRX
Full Company Profile

News

EQRx's Sugemalimab Shows Significant Overall Survival Benefit In Lung Cancer Settings

EQRx Inc (NASDAQ: EQRX), along with its partner CStone Pharmaceuticals has announced data from Phase 3 GEMSTONE-302 trial of sugemalimab plus chemotherapy as a first-line treatment for stage IV non-smal...

5 days ago - Benzinga

Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell ...

CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radicall...

6 days ago - GlobeNewsWire

EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Low...

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radicall...

2 weeks ago - GlobeNewsWire

EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radicall...

3 weeks ago - GlobeNewsWire

EQRx Debuts as Publicly Traded Company to Develop and Deliver Innovative Medicines at Radically Lower Prices

NEW YORK and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences III (Nasdaq: CMLT, CMLTW, CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affi...

1 month ago - GlobeNewsWire

Corvex, Casdin Backed SPAC To Merge With EQRx In $1.8B Deal

CM Life Sciences III Inc (NASDAQ: CMLT), the third SPAC backed by Eli Casdin's Casdin Capital LLC and Keith Meister's Corvex Management LP, is set to merge with EQRx Inc (NASDAQ: EQRX). The stock will l...

5 months ago - Benzinga

Here are the benefits of SPAC deals

Eli Casdin, the chief investment officer of Casdin Capital, joins Keith Meister, CEO of Corvex Management, on the Halftime Report to discuss their SPAC deal with EQRX, a biotechnology company.

5 months ago - CNBC Television